NEW YORK (GenomeWeb News) – Skyline Diagnostics and Clavis Pharma today announced a deal to investigate gene expression biomarkers that may help determine which patients will benefit from a drug compound being developed for treating acute myeloid leukemia.
Under the agreement Skyline will investigate the biomarkers for use with Clavis' elacytarabine, a novel elaidic acid derivative of cytarabine currently undergoing the CLAVELA phase III study for treating patients with relapsed/refractory AML. The study is an open-label, randomized, controlled trial to demonstrate the effectiveness of elacytarabine compared to other current therapies, according to Clavis' website.
Athos Gianella-Borradori, chief medical officer of the Oslo, Norway-based drug firm, said in a statement that Skyline's expertise "will be instrumental in searching for gene expression patterns that can be utilized in the further biomarker program for elacytarabine."
Financial and other terms of the deal were not disclosed.
Based in Rotterdam, The Netherlands, Skyline develops array-based diagnostics tests.